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Parkinson’s disease (PD) affects at least 10 million people worldwide. It is a neurodegener-
ative disease, which is currently diagnosed by neurological examination. No neuroimaging
investigation or blood biomarker is available to aid diagnosis and prognosis. Most effort
toward diagnosis using magnetic resonance (MR) has been focused on the use of
structural/anatomical neuroimaging and diffusion tensor imaging (DTI). However, deep
brain stimulation, a current strategy for treating PD, is guided by MR imaging (MRI). For
clinical prognosis, diagnosis, and follow-up investigations, blood oxygen level-dependent
MRI, DTI, spectroscopy, and transcranial magnetic stimulation have been used. These
techniques represent the state of the art in the last 5 years. Here, we focus on MR
techniques for the diagnosis and treatment of Parkinson’s disease.
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Introduction
Parkinson’s disease (PD), amovement disorder related to dopamine insufficiency in the brain, affects
at least 10 million people worldwide. PD is one of the most complex neurodegenerative diseases,
with a broad spectrum of motor and non-motor symptoms (1). According to the United Kingdom
Parkinson’s Disease Society Brain Bank, clinical diagnosis is based on the presence of two or three
motor features: bradykinesia, plus rigidity, or tremor at rest (or both). However, these criteria do
not separate PD from the many other forms of parkinsonism, nor do they consider the non-motor
symptoms. Despite extensive research, no effective therapy is currently available to prevent the onset
of the disease, or to halt its progression (2).
There is growing evidence that non-motor symptoms may precede motor symptoms – and a
Parkinson’s diagnosis – by years. As the disease progresses and dopaminergic neurons continue
to be lost, the motor symptoms appear and neuroimaging is useful for diagnosis, but by then it
is too late for neuroprotection. No specific life expectancy prediction exists for PD patients after
confirmation of the disease, but mortality rates are double those of healthy individuals at the same
age. The relationship between dopaminergic neuronal loss and non-motor and motor symptoms is
shown in Figure 1. This image is based in an extensive review in the field as well as some of the
images and results from Shapira et al. (3). We use a time span for progression of 18 years, which is
an arbitrary choice, as survival will be unpredictable at these stages of the disease.
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FIGURE 1 | Progression of Parkinson’s disease. Degeneration of
dopaminergic neuronal loss is correlated with motor and non-motor
symptoms in PD patients. The graph starts at a time 0 when
dopaminergic neuronal loss starts, and ends after 18 years, which
was selected arbitrarily as no large physiological changes are
expected after 10 years. When motor symptoms increase, significant
neuroimaging differences can be found using MR and TMS
techniques.
Magnetic resonance (MR) technologies are based on the use
of magnetic fields and radio-frequency pulses to obtain anatom-
ical images. Imaging is the most common application of MR,
but the strength of this technology lies in the fact that many
other measurements can be made. Some examples of these
methods are presented in this review, including blood oxygen
level-dependent functional magnetic resonance imaging (BOLD-
fMRI, a measurement of hemodynamics), perfusion (the process
involved in the delivery of nutritive blood to the brain tissue
capillary bed), and spectroscopy (measurement of the chemical
content of a tissue). We also discuss transcranial magnetic stimu-
lation (TMS) technologies, including simple pulse and repetitive
TMS (4–6).
To date, published data support the use of MR imaging (MRI)
for the diagnosis and treatment of PD (7, 8). There is also a large
amount of work published on MR techniques, such as resting
states fMRI (RS) and diffusion tensor imaging (DTI), as well as
functional connectivity changes in the presence of the disease
[e.g., Ref. (9, 10)]. Several systematic reviews have addressed
the treatment applications for PD that may be combined with
MR techniques. There are two primary ones, namely, focused
ultrasound (11) and deep brain stimulation (DBS), both guided
by MRI (12). To complement all of this excellent previous work,
we address those additional techniques, which are notmainstream
applications of MR to PD. Data from these studies inform neu-
roimaging, clinical follow-up, and possible intervention to treat
PD. Here, we review highly specialized MR-based techniques for
the diagnosis and treatment of PD.
Methods
We followed the PRISMA model (Preferred Reporting Items
for Systematic reviews and Meta-Analyses, http://www.prisma-
statement.org/). We performed a search of articles cited in
PubMed, Web of Science, Scopus, and SciELO from 2009 to 2014
using the following MeSH terms (Medical Subject Headings):
“Parkinson’s disease” and “drug therapy,” “blood oxygen level
dependence,” “functional magnetic resonance imaging,” “diffu-
sion tensor imaging,” “spectroscopy,” or “transcranial magnetic
stimulation.” We found a total of 424 studies related to PD and
these MR/TMS techniques. After filtering publications using all
the criteria previously introduced, 61 articles remained for these
terms, which are presented and discussed in this study. In addi-
tion, we included nine articles published before 2009, since they
pioneered the topic and are necessary for our discussion.
Results
BOLD-fMRI Studies in Parkinson’s Disease
Blood oxygen level-dependent functional magnetic resonance
imaging is a technique, which, in general terms, gives information
about regions that are activated in the brain when performing
a task. This information is obtained by measuring the hemody-
namic changes produced in the activated region due to neuronal
activity. The main limitation of this technique is that the rela-
tionship between neural activity and blood oxygenation has not
been completely characterized. It is also significantly limited by
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the temporal resolution of the measurements, as they depend on
hemodynamic effects (changing on the order of seconds), which
are slow compared to neuronal activations (order ofmilliseconds).
As one might suspect, due to the etiology of PD, the areas most
hypothesized to be affected are those related to the dopamin-
ergic system, specially the substantia nigra, as well as all motor
regions (13).
Blood oxygen level-dependent functional magnetic resonance
imaging studies for PD over the last 5 years can be divided
into two groups. First, there are studies that assess the effect
of medication on BOLD activation. Second, there is research
focused on task-related experiments, which highlight the brain
areas affected by PD.
Effect of Medication on BOLD-fMRI Activation
in PD
It is important to know, when a task-based BOLD-fMRI exper-
iment is performed, the confounding effects that patients under
medication may be subject to. Even though BOLD mechanisms
are not perfectly described, they are known to be affected by
changes in the flow and volume of fresh and deoxygenated blood.
Common drugs can be used to investigate brain activation in
PD patients. Levodopa corrects dopamine depletion in the brains
of PD patients, by increasing dopamine concentrations. In con-
trast, apomorphine is a dopamine agonist, which binds to the
corresponding receptors, creating a detectable electrical signal
for this neurotransmitter. There is a large body of results, which
shows that levodopa does, in fact, affect hemodynamic param-
eters. An example of this research is the paper by Kraft et al.,
which shows how the thalamus and the putamen have reduced
BOLD responses in the absence of levodopa, but return to base-
line with it (14). However, this effect was not found in cortical
structures. Furthermore, Buhmann et al. showed that BOLD acti-
vation in the primary and supplementary motor areas (SMAs)
increases in patients under levodopa, when compared to drug-
naive patients (15). This increase was ratified by Ng et al., with the
extra finding of changes in the spatial extent of BOLD activation,
which were similar between controls and levodopa PD patients
(16). Finally, in recent work by Martinu et al., medication with
levodopa was found to increase corticostriatal motor network
activations, during finger tap movement, in a medicated group
compared to a medication-free group (17). Apomorphine studies
showed an inverted effect, relative to levodopa, with reduced
activation in the contralateral precentral gyrus when performing
a tapping task after drug administration (18). Even though the
majority of research points toward a large effect of medication
on BOLD findings in PD, there is some evidence against it. The
limitation of these investigations lies in the fact that they are
focused on a hypercapnic model. Similar vasoreactivity to hyper-
capnia for patients with and without levodopa treatment has been
observed (19).
BOLD-fMRI Task Experiments in Parkinson’s
Disease: Areas Activated
The most common tasks used in PD studies with BOLD-fMRI
are presented in Table 1. Almost all pharmacological studies
presented in the previous section, and those found in the literature,
used the finger tapping task, which makes it the most-used proto-
col to study BOLD-fMRI activation in PD (20–29).
The SMA is known to be involved in modulating bimanual
movements and sequencingmotion, while the pre-supplementary
motor area (pSMA) is known to connect the prefrontal cortexwith
the spinal cord. If etiological and pharmacological information is
merged with the (real or imaginary) motion studies outlined in
Table 1 for PD patients, both structures show an activation deficit.
These results were logical, and accounted for the movement dis-
order component of PD. A new motion task (more complicated
than finger tapping), whichwas being used to detect PD in its early
stages, also showed hypoactivation in motor regions, such as the
cerebellum, and bilaterally in the SMA (30). The relevance of this
last study was that the reduced cortical activity in primary motor
cortex and SMA in PD patients did not initially relate to motor
symptoms (31).
The precuneus is known to be involved in memory, self-
awareness, consciousness, and visuospatial function (attention
detection). The precuneus was a region found to have weaker
activations in PD patients during a series of different tasks (tactile
stimulation, decision-making, and time perception) (13, 32). This
region was not expected to be activated, as it did not belong to
the group of basal ganglia and motion structures affected by PD.
Hypo-activations in the precuneus were observed during tasks,
which did not requiremotion (33). These studies detected a deficit
in retrieval of episodic and contextual memories, which are useful
for interpretation of tactile stimuli as well as decision-making and
awareness of the passage of time.
The main message we can draw from this section is that, as
expected, almost all research demonstrated at least one substruc-
ture of the basal ganglia to be hypoactive during BOLD-fMRI
studies. This hypoactivity was also shown in brain structures
related to motion. When other structures produced a hypoactive
BOLD signal, it was mainly due to the stimulation protocol used.
This was the case for the precuneus and the ventral striatum
during texture or gambling protocols. Finally, all of these findings
must be taken cautiously, as medication was found to influence
the enhancement or reduction of BOLD activity.
Perfusion Studies in Parkinson’s Disease
Magnetic resonance perfusion measurements are techniques,
which use contrast agents or the magnetic properties of blood to
measure flow, transit time, time to peak, and volume of blood to
a given tissue over time. There are three techniques used in MR:
two with gadolinium as a contrast agent – dynamic susceptibility
and dynamic contrast enhanced MR perfusion – and another
with arterial spin labeling (ASL), which uses blood as the contrast
agent (34). For details of some aspects of this technology see
Ref. (35). New methods, more specific than traditional ASL, are
now starting to become available. Even though perfusion tech-
niques for clinical diagnosis and treatment monitoring are still
in their infancy, the precision of new MR perfusion methods
now rivals that of nuclear medicine or computed tomography.
In the near future, these new techniques are expected to comple-
ment and overtake nuclear medicine, as they do not need nuclear
radiotracers or artificial contrasts (36), making clinical studies
non-invasive, and easy to perform.
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TABLE 1 | Task-based BOLD-fMRI studies focusing on the brain areas affected in Parkinson’s disease.
Task Group description Activity of group 1 higher that group 2 Activity of group 1
low that group 2
Reference
Tactile
stimulation
PD patients (1) vs. healthy control volunteers R. primary sensory, R. motor cortex,
R. supplementary motor area, B. caudate,
B. precuneus, B. occipital visual cortex, L. and
M. temporal gyrus
(23)
Time perception
task
PD patients (1) vs. healthy control volunteers
and medical patients (2)
Precuneus (after long stimuli) (26)
Gambling Non-Pathological gamblers whit PD (1)
vs. Pathological gamblers with PD (2)
B. anterior cingulate cortex, M. and S. frontal gyri,
precuneus, R. I. parietal lobule, ventral striatum
(24)
Imaginary gait PD patients experiencing freezing (1) vs. PDs
not experiencing freezing (2)
R. globus pallidus, R. supplementary motor area,
R. mesencephalic locomotor region,
R. cerebellum, B. anterior insula, B. ventral
striatum, B. pre-supplementary motor area,
L. sub-thalamic nucleaus
(28, 29)
Hand movement PD patients with (1) and without (2) mirror
movements syndrome
R. dorsolateral prefrontal cortex, M. prefrontal
cortex, Pre-supplementary motor area, Occipital
Cortex
B. insula, B. posterior
cingulate cortex, L inferior
frontal cortex
(27)
Balloon analog
risk task
PD patients with an impulse-control disorder
(1) vs. PD patients without and impulse-control
disorder (2)
R. ventral striatum (25)
Speech PD patients (1) vs. healthy control volunteers Primary orofacial sensorimotor cortex (20)
Saccade PD patients (1) vs. healthy control volunteers Frontal and supplementary eye fields L. and R. cerebellum
contralateral motor cortex
(22)
Finger tapping PD patients (1) vs. healthy control volunteers Putamen, supplementary motor area R. prefrontal cortex,
R. caudate
(21)
Here, we show the results from BOLD-fMRI studies performed on PD patients in the last few years. Data are presented in five columns. The task and ability involved appears first.
A description of the groups compared is presented in column two. Column three shows areas of the brain with significant differences, which were smaller for the first group vs. the
second. The fourth column is similar to the third but with an inverted comparison. The last column presents the author and year of publication.
L, left; R, right; B, bilaterally; M, medial; S, superior.
Differences in blood perfusion have already been reported in
multiple brain regions. For example, hypoperfusion was observed
in the posterior cortex for both non-demented and demented PD
patients, when compared to controls (37). Rao et al. also showed
that flow to the right ventral striatum (a reward hub) diminished
in PD patients with an impulse-control disorder, when compared
to thosewithout it (25). In a recent study by Fernández-Seara et al.,
in which absolute cerebral blood flow was measured with ASL
techniques, hypoperfusion was found all over the cortex, and in
some subcortical areas, such as the caudate nucleus (38). As the
whole brain was investigated, and no global mean normalization
was performed on the data, the possibility of artifacts due to this
correction was negligible.
Pulsed arterial spin labeling (PASL), pseudocontinuous arte-
rial spin labeling (PCASL), and continuous arterial spin labeling
(CASL) are techniques, which apply a continuous RF pulse during
which there is a continuous inversion of the arterial blood. An
example of this was the work byMa et al., in which CASLwas used
to measure the disease-related spatial covariance pattern of PD
patients (25). This parameter was elevated in PD patients. When
compared to standard 18F-fluorodeoxyglucose positron emission
tomography studies, similar results were found. Another study
using CASL techniques has also showed promising results in
the early diagnosis of parkinsonian patients (39). The authors
showed decreased cortical perfusion bilaterally to the posterior
and inferior parietal, temporal, insular, lateral occipital, and pre-
frontal association cortices. Some increases were also seen in the
cerebellum, pons, pallidum, right thalamus, sensorimotor cortex,
SMA, and paracentral lobule.
It has also been shown that the differences in brain blood
flow between patients with Alzheimer’s disease (AD) and those
with PD and dementia are not that major, suggesting a closely
linked mechanism for neurodegeneration (translational neurode-
generation). Absolute blood flows were similar for both groups,
although hypoperfusion was found in the posterior cingulate
gyrus, precuneus, and occipital regions, when the disease groups
were compared with controls. PD patients had greater perfusion
in the temporal lobes compared to AD patients, while the latter
had greater perfusion in the right frontal cortex (40).
Finally, in work from Brusa et al., which performed perfusion-
weighted dynamic susceptibility imaging, MR studies of PD
patients showed that the effect of apomorphine medication on
perfusionwas to return the parameters toward the values obtained
from control volunteers (41).
Pharmacological Techniques Meet MR
Technology
Other applications of perfusion methods are pharmacological
tests, which assess the uptake of a drug and its effects in patients.
Perfusion MRI can provide rapid, quantitative, clinically relevant
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dose-finding information for pharmaceutical development. In one
example of a pharmacological study in the PD field, an adenosine
A2a antagonist (SYN115) was given to patients under levodopa
but with no other antagonists. SYN115 produced a decrease in
thalamic cerebral blood flow. Similar decreases occurred in corti-
cal regions whose activity decreased with increased alertness and
externally focused attention (42).
In conclusion, regions matching those found using BOLD-
fMRI were observed to be hyper- or hypoperfused in perfusion
studies. In general, the areas, which presented lower BOLD signals
in PD patients, were found to be less perfused than in controls.
This correlation is to be expected, as cerebral blood flow and
cerebral blood volume are vital components of the BOLD signal.
As before, medication had a confounding effect on the results
obtained with this technique. An advantage of MR perfusion
over BOLD-fMRI was that results were more centralized in the
parenchyma of the brain, rather than its vascularity. As results
continue to pile up, it is becoming obvious that findings from
nuclear medicine are being closely matched and mirrored by MR
perfusion techniques.
Spectroscopy Studies in Parkinson’s Disease
Nuclear magnetic resonance spectroscopy (MRS) is performed
in spectrometers, which differ from normal MR scanners in that
they lack magnetic gradients. MRS techniques do not produce
images, but give information about the presence and quantity of
a particular chemical in a given piece of tissue. For this reason,
they are mainly used to monitor metabolic changes and serve as
non-invasive biopsies. Some of the most common species mea-
sured are 1H, 31P, 13C, and 23Na. MRS can also measure more
complex compounds, such as creatine, glucose, alanines, and lac-
tates (present in some kinds of tumors). For the specific case of
PD, the concentration of N-acetyl aspartate (NAA) is a powerful
biomarker for assessing neuronal loss (12), while choline gives a
good idea of membrane turnover, and creatine (Cr) can be used as
a proxy for energy metabolism. Other parameters, like the ratio of
choline (Cho) to Cr, the NAA-to-Cr ratio, GABA and phosphorus
(associated with molecules of adenosine triphosphate) are also
used for spectroscopy studies of PD. The down-side to these
techniques is the need for very strong magnetic fields, in order
to obtain measurable signals from compounds, which are much
less abundant than the 1H species measured in normal MRI.
This limits the hardware and technology available as well as the
availability, and hence usefulness of the technique.
There is a large body of work using this technique in PD. We
present some of the most recent findings in Table 2. The table
shows that results obtained from MRS should be further divided,
considering possible comorbidities as well as the stage at which
the PD patients were studied. For example, NAA-to-Cr ratios have
been found to be reduced in the SMA, when compared to healthy
volunteers (43). All these results were furthered, showing that
these differences were not significant when comparing controls
with patients at an early stage of PD (44). Nevertheless, motor
function improved after 6months of treatment with pergolide
(dopamine agonist). This improvement was correlated with the
increase of the Cho/Cr ratio found in motor areas (45). Another
example is the comparison of PD patients with or without demen-
tia. In this case, the concentration of NAA in the occipital lobes
was reduced in the demented group, when compared to non-
demented PD patients Fayed (46).
In a recent study, spectroscopy techniques were applied not to
a given region but to the whole brain. Here, NAA, total Cr, and
total Cho were measured and ratios were calculated for the white
and gray matter, as well as for each brain lobe. The main finding
was that a general increase in Cr for PD patients was observed
in an early stage of the disease, when compared to controls. The
authors hypothesized that this result reflected a compensatory
greater neuronal energy expenditure in early PD Levin (53).
TABLE 2 | Spectroscopic studies in Parkinson’s disease.
Group description Affected region Chemical or
ratio studied
Variation between group 1 and 2 Reference
Control (Group 1), PD patients (2) SMA NAA:Cr Reduced in PD patients (43)
Control (Group 1), PD patients (2) Motor cortex Cho:Cr and NAA:Cr Reduced Cho:Cr and NAA:Cr in PD patients. Differences in
the Cho:Cr tend to disappear after dopamine treatment
(45)
Control (Group 1), PD patients (2) Posterior cingulate
gyrus
Glu:Cr, NAA:Cr,
Cho:Cr
Reduced Glu:Cr in PD patients (47)
PD patients with mild cognitive
impairment (Group 1) Normal PD
patients (Group 2)
Posterior cingulate
gyrus, occipital lobe
NAA:Cr Reduced NAA:Cr for PD patients with mild cognitive
impairment
(48)
Control (Group 1), PD patients (2) Anterior and posterior
cingulate cortex
NAA:Cr Reduced in anterior cingulate cortex for PD patients. Not in
posterior cingulate cortex
(49)
Control (Group 1), PD patients (2) Substantia nigra NAA:Cr Reduced NAA:Cr for PD patients (50)
Control (Group 1), PD patients (2) Substantia nigra NAA:Cr, NAA:Cho,
NAA:(Cho+Cr)
All ratios reduced for PD patients vs. control. All ratios
reduced damage hemispheres of PD patients vs. healthy
hemisphere
(51)
Control (Group 1), PD patients (2) Putamen, pons GABA Higher for PD patients vs. control (52)
Here, we show results based on spectroscopy in PD patients in the last few years. Data are presented in five columns. The groups compared appear first. The brain area studied is
presented in column two. Column three shows the metabolite or the ratio studied. The fourth column shows the differences in this ratio or metabolite between groups. The last column
presents the author and year of publication.
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A large body of work has been focused on the cingulate cortex
(47–49) as well basal ganglia structures (50–52). Nevertheless, few
studies have focused on other regions also known to be affected in
PD. Some of these regions would be the precuneus, cerebellum,
insula, and the pre- and postcentral gyri. Current trends in MRS
research are toward combining the findings in this field with
results from other MR techniques. An example of this is the
research from Modrego et al., where the authors compared a PD
rating scale withDTI and glutamate and glutamine concentrations
obtained from MRS in the lenticular nucleus (54). They found
that the combined increase of glutamate and glutamine in the
lenticular nucleus in PD patients was correlated with a reduction
in fractional anisotropy in this region. This study showed that a
big dopaminergic loss must happen before related MRS measure-
ments show a difference, proving the hypothesis that there is an
onset of PD, and opening up the possibility of identifying potential
PD sufferers before the onset ofmotor symptoms. Studies focusing
on other ratios or metabolites should follow soon.
Transcranial Magnetic Stimulation in Parkinson’s
Disease
Transcranial magnetic stimulation is a novel tool in which a
coil is placed over the intact skull (4). The coil induces electric
fields in the cortex (a few centimeters in depth), which depolarize
neurons in a region dependent on the shape of the coil and the
current passing through it. If the pulses are triggered repeatedly
and periodically, it is called repetitive TMS (rTMS). Recently, this
approach has been used to treat different neurological and psy-
chiatric disorders, such as epilepsy, attention deficit hyperactivity
disorder, depression, and PD (4, 6, 55). The difficulty with this
technique is the current lack of understanding of its after-effects,
the variability between individuals, the different stimulation pro-
tocols, the range of available study designs, and so on (4, 6).
There is growing evidence that rTMS can be used to treat PD
(4). Recently, TMS applications have focused on three general
lines of research. First, as dyskinesia is thought to be associated
with abnormal plasticity in the motor cortex, TMS techniques
have been used to assess the effects of cortical plasticity (4). Sec-
ond, the effects of TMS and rTMS on muscle function during gait
andmotion, as well as the effects of fatigue, have been investigated
(4). Finally, the inhibitory effect of TMS techniques has been used
to assess which brain regions are involved in the appearance of
comorbidity, or behind a given symptom of PD (seeTable 3). New
information on cognition and different neurodegenerative disor-
ders (e.g., PD, AD, or cognitive dysfunction) has been discussed
elsewhere (56).
For cortical plasticity, first, the effects of medication (usually
levodopa) were assessed by comparing PD patients with and
without dyskinesia. Cortical excitability after rTMSwas similar for
both groups, but inhibition was impaired in the dyskinesia group.
This suggested that levodopa had an abnormal effect on cortical
motor inhibitory circuits for these patients (57). Nevertheless, if
treatment with rTMS was combined with treadmill training, it
was shown that the effects on inhibitory circuitry were potentiated
(58). It has been shown that low frequency rTMSdelivered on con-
secutive days changed the excitability of motor cortex, by increas-
ing the excitability of inhibitory circuits (59). The effects persisted
for at least a day after rTMS. Applications of TMS for studying
TABLE 3 |Magnetic resonance technology in Parkinson’s disease.
Technique Physical principle used Use Applications in PD
Anatomical magnetic
resonance imaging (MRI)
Resonance signal of water
content in tissues
Anatomical marker of
pathologies and injures
Complements PD diagnosis excluding other
Diffusion tensor imaging (DTI) Diffusion of water molecular in
tissues
Marker of whit matter
connections
Detecting white tract degeneration to use as biomarker
Resting state functional
magnetic resonance (RS-MRI)
Low frequency oscillations of
BOLD response
Indirect marker of neural
connectivity
Study alterations of resting state networks due to PD. This
aimed at finding a biomarker for diagnosis, as an indicator of
treatment viability and as an indicator of the neurophysiology
under symptoms from PD. Also used to study cortical plasticity
Functional magnetic
resonance imaging
(BLOD-fMRI)
Magnetic properties of blood Indirect marker of neural
activity (hemodynamic
response)
Hypo–active Blood-fMRI signals in basal ganglia as well as
motion brain structures for PD patients. Big influence of
medications on result
Magnetic resonance
spectroscopy (MRs)
Spectroscopic properties of
chemical components of tissues
Marker of the amount of
chemicals in tissues
Neuronal loss on basal ganglia assessed thought the NAA:Cr
ratio. Increased GABA and decreased NAA:Cho,
NAA:(Cho+Cr) for PD patients vs. Control
Magnetic resonance
perfusion (MRP)
Flow and its characteristics in
and outs tissues using RF pulses
Marker of: flow, transit time,
time to peak and volume of
blood to a tissue
Hypo–perfusion in same regions in which BLOD-fMRI
presented hypo-activations for PD patients
Transcranial magnetic
stimulation (TMS)
Induction of electrical and
magnetic fields in a tissue using
RF pulse
Activation and deactivation of
brain regions
Assessment of the effects of cortical plasticity. Effect of TMS
and rTMS on muscle function. Assessment of brain regions
involved in PD symptoms production
Repetitive transcranial
magnetic stimulation (rTMS)
As TMS, but repeated regulatory As TMS but with regular
repetitions
Assessment of the effects of cortical plasticity. Effect of TMS
and rTMS on muscle function. Assessment of brain regions
involved in PD symptoms production
The first column shows MR techniques used for the diagnostic and research of PD. The second presents the physical properties of the technology used. The third, the use they have
in general, and the fourth, specific applications in PD studies.
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cortical plasticity in PDpatients have produced conflicting results,
as some studies showed increases in long-term potentiation at the
neuronal level, while others have shown decreases the opposite
result. Some authors have suggested that these differences arose
from the chemical treatments patients were undergoing and also
from the stage of the illness (60). Some work with rTMS included
the development of new protocols like quadruple pulse stimula-
tion (QPS), in which TMS pulses were separated by interstimulus
intervals of 5ms (QPS-5) and 50ms (QPS-50). This setup induced
bidirectional motor cortical plasticity. The short interval induced
a potentiation effect, and the long interval a depression. Authors
also reported a mediating effect of levodopa in their results (61).
The effects of TMS and rTMS on muscle function during gait
and complex motion are also influenced by muscular fatigue. It
is important to establish that the classical finger tapping test used
for PD studies had to be limited to activations during comfort-
able performance of the task. If an extremely fast finger tapping
movement was performed, then fatigue appeared as a constraint
on the motor evoked potentials (MEPs) induced by TMS (62).
The problem lay in the fact that this confound was not of cortical
origin, so it was not a PD-related confound. A report, studying
PD patients and comparing them to healthy subjects during TMS
experiments (applied to the vertex), has shown that after con-
traction of the adductor muscle, normal subjects presented an
initial gradual reduction inMEPs in their electromyography-silent
period until the endurance point, and then an increase in these
parameters. This effect was completely dissociated for PD patients
who show impairment in the cortical compensatory mechanisms
that healthy subjects have (63). Gait improvement (as well as
cognitive function) was found in patients treated with rTMS in
the dorsolateral prefrontal cortex (DLPFC), when combined with
galantamine (64). The latter is an acetylcholinesterase inhibitor,
which has a role in cognition as a memory modulator, and is
known to reduce hallucinations in PD patients. The application
of rTMS in the SMA has been found to improve handwriting
in PD patients, ostensibly by changing the excitability of cortical
networks throughout the brain (65). This last result was also sup-
ported byMaruo et al., who found that rTMS applied to themotor
regions reduced the motor symptoms of PD patients (66). This
was achieved over a single session, but several patients required
the effect to bemaintained for longer periods of time. Intermittent
theta bursting (iTBS) has shown similar results to this work (67).
In studies of rTMS on PD patients with dysarthria, treatment of
the primary sensorimotor areas led to an improvement in voice
quality and intensity, as well as an increase in speech rate and
tongue movements (68).
In the third line of work addressed, the involvement of the
cerebellothalamocortical (CTC) pathway that affects motion has
also been assessed using TMS. This technique was applied to
the primary motor cortex and the cerebellum of PD patients,
and compared to results from a healthy group. Cerebellar inhibi-
tion was found to be reduced in PD patients. Rest tremors were
affected by primary motor stimulation, while postural tremors
were affected by both stimulations. This pointed toward involve-
ment of different regions of the CTC in the transmission and
generation of tremors (69). In other work by Nardone et al.
(70), rTMS was applied to the DLPFC of PD patients with the
compulsive disorder known as punding. The idea was to break
the links between prefrontal structures and the striatum, which
were thought to be responsible for these effects. The experiment
was successful, and effects were found to be equivalent to those of
levodopa in PDpatients where the drug corrected this connection.
Progress using rTMS has been achieved through the use of
animal models. In work by Hsieh et al., the scientists proved
that a combination of rTMS and iTBS modulated motor activ-
ity in cortex, and suggested the possibility of using this model
for treatment of early PD patients (71). They also found that
this model worked only for animals, which had not yet lost the
majority of their dopaminergic neurons in the substantia nigra,
indicating that preservation of these neurons may be a biomarker
for the usefulness of rTMS and TMS in general. Another murine
model has been used to assess the therapeutic effects of rTMS
on dopaminergic neurons of PD in animals (72). The treatment,
when compared to controls which received sham rTMS, produced
significant changes including improvement in treadmill locomo-
tion and increased tyrosine hydroxylase-positive dopaminergic
neurons, as well as dopaminergic fibers in striatum and substantia
nigra. All this shows that rTMS has a neuroprotective function
(73). New techniques like deep rTMS (rDTMS), which uses H-
coils to allow for a deeper and more widespread stimulation, have
been used to improve theUnified Parkinson’s Disease Rating Scale
(UPDRS) scores significantly when stimulating primary motor
and prefrontal cortex bilaterally (74).
Recently, there has been a trend toward combining TMS and
rTMS with other techniques as BOLD-fMRI (75). In some inter-
esting work, treatment with either fluoxetine or rTMS was given
to depressed PD patients (76). The after-effects were assessed with
BOLD-fMRI. This approach showed that, even when both treat-
ments improved the mood disorder, different cortical areas were
activated. rTMS increased activity in the left DLPFC and anterior
cingulate gyrus, while fluoxetine did so in the right premotor
and right medial prefrontal cortex. Both treatments affected the
left medial prefrontal cortex but in different ways (effects were
group and time dependent). This work shows that the different
treatments had different effects on brain function and affected
regions.
Conclusion
Here, we have described novelMR and TMS techniques for study-
ing PD. A summary of the results presented here can be seen
in Table 3. The fact that these MR/TMS techniques are not as
commonly used as DBS or normal structural MRI does not imply
that they are ineffective; in fact, all of them contribute to the
knowledge we have about PD. The BOLD-fMRI technique and
perfusion MR have been focused on the regions known to be
affected in PD (basal ganglia, motor, and prefrontal cortex). Both
techniques showed hypoperfusion and smaller BOLD signals in
these regions in PD patients, compared to controls. Spectroscopic
findings worked mainly with the NAA-to-Cr ratio as an indicator
of neuronal loss. Other chemical markers have not been used,
but there are several ongoing investigations in this field. TMS has
proven to be a useful tool to treat PD. It has been shown that
it could be possible to knock-out a specific brain region for a
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given period of time, to assess which regions were correlated with
comorbidity and separate different symptoms associated with the
progression of PD. TMS techniques have also been used to assess
cortical plasticity. Current research into future treatments for PD
cannot be fully understood without including all available MR
techniques.
Finally, we must remember that, however, exciting the neuro-
biological mechanisms might be the clinical usefulness of rational
therapeutic approaches will be determined by their ability to
provide efficacy, safety, and long-lasting and substantial improve-
ments to quality of life. It is important that new studies are
designed using criteria and end-point measures specific to differ-
ent stages of PD, which will allowmore definitive conclusions and
understanding of this disease.
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